Evidence · idea-019

No FDA 510(k) clearance and no De Novo grant for a device indicated to treat orthostatic hypotension (neurogenic or otherwise) by automated, posture-triggered abdominal or splanchnic compression was identified by the Generator's web search.

Devices marketed as elastic or hook-and-loop abdominal binders are widely sold in the US as general support garments without an orthostatic-hypotension treatment claim, and abdominal binders are described in published consensus guidance on the management of neurogenic orthostatic hypotension as a non-pharmacologic measure.

No device of this candidate's design exists as a prototype, and no bench, animal, or human data exist for it specifically; every performance property attributed to it in this file is design intent.

HCPCS Level II codes E0650, E0651 and E0652 exist for pneumatic compressors, and the code family includes appliance codes for trunk and chest application (the Generator believes E0656 and E0657, not confirmed). No HCPCS code specific to a powered, posture-triggered abdominal compression device indicated for orthostatic hypotension was identified.

Midodrine and droxidopa are FDA-approved prescription drugs for symptomatic orthostatic hypotension (droxidopa's approval being specific to symptomatic neurogenic orthostatic hypotension in primary autonomic failure and related conditions), both dispensed as outpatient pharmacy benefit rather than under the Part B device benefit, and both carry labeled supine-hypertension risk.

Public Law 114-255 section 3051 added section 515B to the Federal Food, Drug, and Cosmetic Act (codified at 21 U.S.C. 360e-3), establishing the Breakthrough Devices Program, under which a device may qualify where it provides for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human disease or conditions and either represents a breakthrough technology, has no approved or cleared alternatives, offers significant advantages over existing approved or cleared alternatives, or where availability is otherwise in the best interest of patients.

TAM component 1 of 4 — population base: approximately one million people in the United States are living with Parkinson disease and approximately 90,000 are newly diagnosed each year.

TAM component 3 of 4 — price per unit: the Generator assumes a device selling price and a Medicare allowable in the range of existing DMEPOS pneumatic-compressor purchase allowables under HCPCS E0650-E0652, and asserts no specific figure. No payment rate was extracted from any CMS fee schedule.

TAM component 4 of 4 — addressable share: the Generator assumes that the addressable population is the subset of patients with symptomatic neurogenic orthostatic hypotension who remain symptomatic on non-pharmacologic measures, who have sufficient manual dexterity or caregiver support to don and operate a powered abdominal garment daily, and whose prescribers would choose a device over or alongside a pressor drug. No share figure is asserted and no primary research supports any share figure.

TAM volume anchor: annual Medicare fee-for-service utilization of HCPCS E0650, E0651 and E0652 is published in CMS DMEPOS utilization data and is the checkable volume floor for a device priced into that channel; the Generator extracted no figure and asserts none.

FTO — coverage of the search: beyond the single publication number in the preceding claim, no patent search was performed; the FTO field is otherwise unexamined. No landscape search of posture-sensing compression, servo-controlled pneumatic bladder control, or abdominal-compression-for-hypotension art was conducted, and no assignee search was run against intermittent pneumatic compression incumbents.

Assumption, not a fact: adults with Parkinson disease, multiple system atrophy or pure autonomic failure — a population in which tremor, rigidity, bradykinesia and impaired dexterity are common — would be able and willing, with or without caregiver help, to don, charge, and operate a powered abdominal compression garment daily over a sustained period rather than abandoning it after an initial trial.

Assumption, not a fact: neurologists and autonomic specialists managing symptomatic neurogenic orthostatic hypotension would prescribe a device in an indication currently managed with midodrine and droxidopa, and would accept the documentation burden of a DME prescription and prior authorization to do so.

Assumption, not a fact: patients and prescribers would treat the absence of supine pressure exposure — compression applied only while upright — as a clinically meaningful advantage over pressor drug therapy sufficient to change prescribing, rather than as a theoretical distinction.

Mechanism and clinical-risk reasoning (Generator's own, flagged as reasoning rather than finding): applying 40 mmHg abdominal compression only during upright posture is expected to raise standing blood pressure by reducing splanchnic venous pooling while producing zero supine pressure exposure by construction; the named failure modes are posture-detection error (compression applied while recumbent, or not applied on standing), pressure-sensing or vent failure, skin and abdominal-wall injury under sustained pressure, interference with respiration or with abdominal stomas/feeding tubes in comorbid patients, and reduced effectiveness in patients with high BMI. None of these has been characterized for this device because this device does not exist.

Assumption, not a fact: a home-use, patient-owned, prescription abdominal compression device of this description would fall within the Medicare durable medical equipment benefit category and be separately billable in its own right, rather than being packaged into another payment. The Generator asserts this as design intent; the benefit-category question is decided by CMS, not by the device's form factor.

Assumption, not a fact: a pivotal study in symptomatic neurogenic orthostatic hypotension due to primary autonomic failure would enroll a cohort that is predominantly Medicare-aged, such that Medicare-population clinical outcomes could be designed into the protocol from the start. The Generator asserts no age-distribution figure and cites no registry.

No competitor company was identified by the Generator as currently pursuing FDA clearance, De Novo authorization, or US commercialization of a powered, posture-triggered abdominal compression device for orthostatic hypotension.